Positives

• In the Phase 2 GNC-501 trial, patients tolerated six IV infusions of temelimab very well, with no safety signals across 200 enrollees in Switzerland, Spain, and Italy BusinessWire.
  
  
• Patients with shorter disease duration and changing HERV-W ENV status showed signals of better response in subgroup analyses, suggesting an early-treatment window may exist Altea Network.
  
  

Negatives

• In the GeNeuro Long COVID trial, patients saw no clinically meaningful improvement on the PROMIS SF7a fatigue endpoint compared with placebo, and most secondary endpoints also failed FierceBiotech.
  
  
• A patient screened for HERV-W ENV positivity would discover that only about one-third of Long COVID candidates qualify for the biomarker, narrowing the eligible population GeNeuro.
  
  

Hurdles & Side Effects

• Patients hoping for temelimab will find development effectively halted, with GeNeuro reducing workforce and pursuing strategic alternatives after the failed readout FierceBiotech.
  
  
• A patient who wanted to try the antibody would need both HERV-W ENV biomarker testing and access to monthly IV infusions, neither available outside a sponsored trial Precision Medicine Online.